Floatz logo

FMISO

Stage III Lung Non-Small Cell Cancer AJCC v7

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Stage III Lung Non-Small Cell Cancer AJCC v7 cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

FMISO is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
giant cell glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →